Berndt C, Haubold K, Wenger F, Brux B, Müller J, Bendzko P, Hillebrand T, Köttgen E, Zanow J
Institute of Laboratory Medicine and Pathobiochemistry, Medical Faculty Charité, Humboldt-University, Berlin, Germany.
Clin Chem. 1998 Oct;44(10):2103-7.
Mutant-enriched PCR and reverse dot blot hybridization in microplates were applied for examining K-ras status in stools and tissue samples from patients with pancreatic tumors and chronic pancreatitis. In tissue samples, K-ras mutations were found in 32 of 35 cases of ductal adenocarcinoma, in 5 of 7 periampullary cancers, in 1 cystadenocarcinoma, and in 3 of 5 patients with chronic pancreatitis. In stools, mutated K-ras was seen in 10 of 25 cases of ductal adenocarcinoma, in 1 case of cystadenocarcinoma, and in 2 of 6 cases of chronic pancreatitis. These data indicate that the K-ras status of stool samples may help identify pancreatic carcinoma and persons at risk for cancer development; however, it does not allow discrimination of malignant from nonmalignant diseases.
采用微板中富集突变体的聚合酶链反应（PCR）和反向斑点杂交技术检测胰腺肿瘤和慢性胰腺炎患者粪便及组织样本中的K-ras状态。在组织样本中，35例导管腺癌中有32例发现K-ras突变，7例壶腹周围癌中有5例，1例囊腺癌，5例慢性胰腺炎患者中有3例。在粪便中，25例导管腺癌中有10例检测到K-ras突变，1例囊腺癌，6例慢性胰腺炎患者中有2例。这些数据表明，粪便样本的K-ras状态可能有助于识别胰腺癌及癌症发生风险人群；然而，它无法区分恶性疾病和非恶性疾病。
